Neuropace Stock Investor Sentiment

NPCE Stock  USD 13.52  0.25  1.82%   
About 55% of Neuropace's investor base is interested to short. The analysis of overall sentiment of trading Neuropace stock suggests that many investors are impartial at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.

Comfort Level 45

 Impartial

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Neuropace's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Neuropace.

Neuropace Historical Sentiment

Although Neuropace's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Neuropace, such as negative comments on social media and news outlets, may cause fear in the market and push Neuropace's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Neuropace.
  

Neuropace Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Historical Investor Sentiment

Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuropace news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuropace.

Neuropace Maximum Pain Price Across May 16th 2025 Option Contracts

Neuropace's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Neuropace close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Neuropace's options.
23 hours ago at thelincolnianonline.com         
NeuroPace Expected to Announce Earnings on Tuesday
news
2 days ago at thelincolnianonline.com         
Ltd. Kck Sells 5,270,845 Shares of NeuroPace, Inc. Stock
news
few days ago at zacks.com         
Disposition of 78334 shares by Martha Morrell of Neuropace at 13.7213 subject to Rule 16b-3
zacks News
few days ago at zacks.com         
Integer Misses Q4 Earnings Estimates
zacks News
few days ago at gurufocus.com         
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Disposition of 5270845 shares by Kck Ltd. of Neuropace at 9.4 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Gurufocus Stories at Macroaxis
six days ago at gurufocus.com         
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of ...
Gurufocus Stories at Macroaxis
six days ago at globenewswire.com         
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwrite...
Macroaxis News: globenewswire.com
over a week ago at gurufocus.com         
Kent Lake PR LLC Acquires Additional Shares in NeuroPace Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
NeuroPace Announces Pricing of Public Offering of 65 Million of Common Stock
Gurufocus Stories at Macroaxis
over a week ago at massdevice.com         
Neuromod developer NeuroPace announces 65M offering
news
over a week ago at gurufocus.com         
NeuroPace Prices 65 Million Offering Shares Drop in Pre-Market
Gurufocus Stories at Macroaxis
over a week ago at globenewswire.com         
NeuroPace Announces Pricing of Public Offering of 65 Million of Common Stock
Macroaxis News: globenewswire.com
over a week ago at gurufocus.com         
NeuroPace Announces Proposed Public Offering of 65 Million of Common Stock
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Neuropace that are available to investors today. That information is available publicly through Neuropace media outlets and privately through word of mouth or via Neuropace internal channels. However, regardless of the origin, that massive amount of Neuropace data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuropace news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuropace relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuropace's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuropace alpha.

Neuropace Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
NeuroPaces SWOT analysis epilepsy device makers stock poised for growth
11/25/2024
2
Insider Trading
01/06/2025
3
NeuroPace reports preliminary Q4 revenue
01/08/2025
4
Disposition of 3200 shares by Martha Morrell of Neuropace at 15.01 subject to Rule 16b-3
01/24/2025
5
Disposition of 100 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3
01/29/2025
6
Disposition of 200 shares by Martha Morrell of Neuropace at 15.0 subject to Rule 16b-3
01/30/2025
7
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS ...
02/03/2025
8
Morgan Stanley Reduces Stake in NeuroPace Inc A Strategic Portfolio Adjustment
02/04/2025
9
NeuroPace announces proposed public offering of 65M of common stock
02/13/2025
10
NeuroPace Prices 65 Million Offering Shares Drop in Pre-Market
02/14/2025
11
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
02/19/2025
12
Integer Misses Q4 Earnings Estimates
02/20/2025

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges